therapeutic and prophylactic effectiveness of topical immunomodulator in treatment of acute respiratory infections

Clicks: 287
ID: 161560
2011
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #8 of 111 articles by views in Biocontrol science

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Clinical effectiveness and safety of topical immunomodulator IRS 19 in treatment and prophylaxis of infectious diseases of airways in adults and children was studied in numerous Russian clinical studies. The article reviews the most interesting results of these studies. Administration of bacterial lysates mixture lowers the rate of acute respiratory infections (ARI) and exacerbations of chronic ENT diseases in patients including frequently ailing children. Treatment with the drug results in much smoother disease’s course. Action of a drug shortens terms of a disease, induces significant decrease of ARI complications rate, normalization of nasopharinx biocenose, and lowers the need in antibacterial drugs.

Reference Key
shamsheva2011voprosytherapeutic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;O. V. Shamsheva;N. N. Zvereva
Journal Biocontrol science
Year 2011
DOI
DOI not found
URL
http://vsp.spr-journal.ru:80/jour/article/view/542
Keywords
Children treatment acute respiratory infections prophylaxis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.